Nice rvw of tx for SSc-ILD by @sclerodermaUM et al Endorse: "MMF is now considered the standard of care as first line therapy for the treatment of SSc-ILD" Reasonable chart, but wish we could offer more HSCT Also, I'm seeing a LOT of INappropriate early use of nintedanib https://t.co/n1R73EbrXZ